poisar

Stocks · News reference

Citizens JMP Maintains Buy Rating on Artivion, Adjusts Price Target

Fiscal.ai

Analyst Daniel Stauder of Citizens JMP has maintained a 'Buy' rating on Artivion (AORT) while lowering the price target from $48 to $42.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncThe Insight Partners

    Transcatheter Aortic Valve Replacement Market to Reach US$ 30.01 Billion by 2035 at 15.2% CAGR, Driven by Improved Clinical Outcomes and Increasing Adoption of Catheter-Based Cardiac Interventions | Exclusive Report by The Insight Partners

    The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.

  2. BenzingaBenzinga Insights

    Transcript: Artivion Q2 2026 Earnings Conference Call

    Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our